What is the total value of India's pharmaceutical export to United States?

India exported pharmaceuticals worth $2.7B to United States across 27,607 verified shipments.

Which companies in United States import pharmaceuticals from India?

1. INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED — $74.9M. 2. TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED — $44.0M. 3. ASTRAZENECA PHARMA INDIA LIMITED — $43.9M. 371 buyers total.

What pharmaceutical products does India export most to United States?

1. Vaccine ($957.0M, 34.9%); 2. Serum ($774.4M, 28.3%); 3. Plasma ($538.7M, 19.7%); 4. Dapagliflozin ($92.0M, 3.4%); 5. Fluticasone ($54.3M, 2.0%)

Why does United States import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $2.7B corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply United States?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to United States pharmaceutical trade?

$99.3K per consignment across 27,607 shipments.

How many Indian pharmaceutical companies export to United States?

689 Indian companies. Largest: Takeda Pharmaceuticals International AG with $48.5M.

How can I find verified Indian pharmaceutical suppliers for United States?

TransData Nexus covers 689 active exporters with shipment history and trade values at transdatanexus.com.

United States to India Pharmaceutical Import (2026) — $2.7B, 689 Foreign Suppliers | TransData Nexus

Q: Who are the top Indian pharmaceutical exporters to United States?

1. Takeda Pharmaceuticals International AG — $48.5M. 2. SWORDS LABORATORIES UNLIMITED COMPANY — $45.0M. 3. BOEHRINGER INGELHEIM VETMEDICA GMBH — $36.0M. Total: 689 suppliers.

United States to India Pharmaceutical Import (2026) — $2.7B, 689 Foreign Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — United States to India

#	Formulation	Value	Share
1	Vaccine	$957.0M	34.9%
2	Serum	$774.4M	28.3%
3	Plasma	$538.7M	19.7%
4	Dapagliflozin	$92.0M	3.4%
5	Fluticasone	$54.3M	2.0%
6	Nivolumab	$41.5M	1.5%
7	Immunoglobulin	$40.0M	1.5%
8	Sodium	$29.0M	1.1%
9	Metformin	$18.9M	0.7%
10	Moxifloxacin	$17.0M	0.6%
11	Metoprolol	$15.7M	0.6%
12	Heparin	$14.8M	0.5%
13	Diclofenac	$13.4M	0.5%
14	Prednisolone	$9.3M	0.3%
15	Sitagliptin	$7.3M	0.3%

India imports 20+ pharmaceutical formulations from United States with a combined trade value of $2.7B. Key products include Vaccine ($957.0M), Serum ($774.4M), Plasma ($538.7M), Dapagliflozin ($92.0M), Fluticasone ($54.3M). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 27,607 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — United States to India Trade Routes

1Vaccine$957.0M

2Serum$774.4M

3Plasma$538.7M

4Dapagliflozin$92.0M

5Fluticasone$54.3M

Top United States Suppliers to India

1Takeda Pharmaceuticals International Ag

$48.5M

2Swords Laboratories Unlimited Company

$45.0M

3Boehringer Ingelheim Vetmedica Gmbh

$36.0M

4Intervet International B.v.

$20.0M

5Ceva Animal Health,llc

$19.7M

Trade Statistics

Total Value$2.7B

Shipments27,607

Indian Exporters689

United States Buyers371

Avg Shipment$99K

Products265

Other Import Origins

Germany$929.2M China$767.5M Italy$471.9M France

Last updated: March 28, 2026

India–United States Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The pharmaceutical trade corridor between the United States and India has experienced significant growth over the past two decades. In 2005, the bilateral pharmaceutical trade was valued at approximately $500 million, with around 5,000 shipments. By 2025, this figure had escalated to $2.7 billion, encompassing 27,607 shipments. This expansion underscores the increasing interdependence of the two nations in the pharmaceutical sector.

Key milestones in this evolution include the establishment of the U.S.-India Trade Policy Forum in 2005, aimed at enhancing bilateral trade relations. The signing of the U.S.-India Civil Nuclear Agreement in 2008 also paved the way for deeper economic collaborations, indirectly benefiting sectors like pharmaceuticals. Additionally, India's participation in the World Trade Organization (WTO) since 1995 has facilitated smoother trade processes, including the import of pharmaceutical products from the U.S.

2United States's Role in India's Pharma Imports

The United States plays a pivotal role in India's pharmaceutical imports, accounting for a substantial share of the market. In 2025, the U.S. supplied a diverse range of pharmaceutical products to India, including vaccines, serums, and specialized drugs. Notably, vaccines alone constituted 34.9% of the total import value, highlighting the critical importance of immunological products in the bilateral trade.

India's importation of these products from the U.S. is driven by the need for advanced medical treatments and technologies not readily available domestically. The U.S. pharmaceutical industry is renowned for its innovation and high-quality standards, making it a preferred source for India's healthcare requirements.

United States Regulatory Landscape for Indian Pharmaceutical Exports

Registration process, GMP requirements, import documentation

1CDSCO Registration Process

For U.S. companies aiming to export pharmaceutical products to India, compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations is mandatory. The process involves obtaining an import license under Form 10 of the Drugs and Cosmetics Rules, 1945, and registering the product with CDSCO under Form 41.

The registration process requires submission of comprehensive documentation, including a Certificate of Analysis (CoA) for each batch, a Good Manufacturing Practice (GMP) certificate from the exporting country, and an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). Additionally, an authorization letter from the manufacturer or marketing authorization holder (MAH) is necessary, authorizing the Indian importer to import specific pharmaceutical products on their behalf.

2GMP & Manufacturing Standards

India mandates that pharmaceutical products imported from the U.S. be manufactured in facilities compliant with Good Manufacturing Practice (GMP) standards as prescribed by CDSCO. The manufacturing facilities must meet specific requirements concerning premises, plant, machinery, and quality control processes. Compliance with these standards ensures the safety, efficacy, and quality of pharmaceutical products available in the Indian market.

3Import Documentation

Importing pharmaceutical products into India necessitates several key documents:

Import License (Form 10): Issued by CDSCO, this license authorizes the importation of specific pharmaceutical products.

Registration Certificate (Form 41): Also issued by CDSCO, this certificate confirms that the imported product is registered for sale in India.

No Objection Certificate (NOC): Required for certain products, this certificate indicates that the product does not violate any existing patents or trademarks in India.

Test License: Permits the import or manufacture of drugs for testing, analysis, or clinical trial purposes.

Customs Documentation: Includes the Bill of Entry and other customs declarations necessary for clearing goods through Indian customs.

Ensuring all documentation is accurate and complete is crucial for the smooth clearance of pharmaceutical imports.

TransData Nexus Research · United States regulatory databasesMar 2026

Product Categories & Therapeutic Trends — India to United States

Dominant categories, emerging opportunities, and demand drivers

1Dominant Import Categories

The pharmaceutical imports from the United States to India are predominantly in the categories of vaccines, serums, and specialized drugs. Vaccines alone accounted for 34.9% of the total import value, underscoring their critical role in India's healthcare system. Serums and plasma products also constitute significant portions of the imports, reflecting the demand for advanced biological products.

Specialized drugs, including Dapagliflozin, Fluticasone, and Nivolumab, are imported to address specific therapeutic needs not met by domestic products. These imports are essential for treating complex health conditions and contribute to the advancement of medical treatments in India.

2Innovation & Specialty Imports

India's importation of innovator drugs and novel formulations from the United States is driven by the need for advanced therapies not manufactured domestically. Products like Dapagliflozin, Fluticasone, and Nivolumab are examples of specialized drugs imported to meet specific therapeutic requirements. These imports are crucial for addressing complex health conditions and advancing medical treatments in India.

3Import Demand Drivers

India's importation of pharmaceutical products from the United States is influenced by several factors:

Patent Protection: The U.S. offers strong patent protection, ensuring that innovative drugs are available for import without generic competition.

Technology Gaps: Certain advanced pharmaceutical technologies and formulations are not yet developed domestically, necessitating imports to meet healthcare needs.

Quality Requirements: The U.S. pharmaceutical industry is renowned for its stringent quality standards, making its products highly desirable in the Indian market.

Disease Burden: The prevalence of specific diseases in India creates a demand for specialized treatments that are often sourced from the U.S.

These factors collectively drive the sustained demand for U.S. pharmaceutical imports into India.

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to United States identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 27,607 verified shipments from 689 Indian exporters to 371 United States buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

689 Exporters

371 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

United States to India Pharmaceutical Import

Top Pharmaceutical Formulations — United States to India

Top Pharmaceutical Products — United States to India Trade Routes

Top United States Suppliers to India

Trade Statistics

Other Import Origins

India–United States Pharmaceutical Trade Corridor Analysis

1Trade Corridor Evolution

2United States's Role in India's Pharma Imports

Top Indian Buyers from United States

Product Routes

Full Dataset Access

3Recent Developments

United States Regulatory Landscape for Indian Pharmaceutical Exports

1CDSCO Registration Process

2GMP & Manufacturing Standards

3Import Documentation

Product Categories & Therapeutic Trends — India to United States

1Dominant Import Categories

2Innovation & Specialty Imports

3Import Demand Drivers

Trade Policy & Tariff Intelligence — India and United States

1India's Import Tariff Structure

2Trade Agreements & Preferences

3IP, Patents & Price Control

Supply Chain & Logistics — India to United States Pharma Shipments

1Shipping Routes & Transit

FAQ — India to United States Pharmaceutical Trade